<?xml version="1.0" encoding="UTF-8"?>
<p>Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related mortality. An estimated 1033 700 new gastric cancer cases and 782 700 deaths occurred (
 <xref rid="ref1" ref-type="bibr">1</xref>). Curative resection with perioperative adjuvant treatment is the standard treatment for locally advanced gastric cancer worldwide (
 <xref rid="ref2" ref-type="bibr">2</xref>). In Asia, D2 gastrectomy and postoperative adjuvant chemotherapy with S-1, S-1 and docetaxel, or capecitabine and oxaliplatin is the standard treatment (
 <xref rid="ref3" ref-type="bibr">3</xref>). However, the recurrence rate was reported to 30–40%, even after curative treatment. In addition, it was previously reported that macroscopic type 4, large (diameter &gt;8 cm) macroscopic type 3, and bulky lymph node metastasis have been reported as prognostic factors in locally advanced gastric cancer (
 <xref rid="ref4" ref-type="bibr">4</xref>,
 <xref rid="ref5" ref-type="bibr">5</xref>). Aggressive treatment is needed to improve the survival of patients with locally advanced gastric cancer who have risk factors for severe disease.
</p>
